ES8703525A1 - Un metodo para preparar una vacuna viva, no virulenta - Google Patents

Un metodo para preparar una vacuna viva, no virulenta

Info

Publication number
ES8703525A1
ES8703525A1 ES549285A ES549285A ES8703525A1 ES 8703525 A1 ES8703525 A1 ES 8703525A1 ES 549285 A ES549285 A ES 549285A ES 549285 A ES549285 A ES 549285A ES 8703525 A1 ES8703525 A1 ES 8703525A1
Authority
ES
Spain
Prior art keywords
atcc
continuation
deposited
serial
september
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES549285A
Other languages
English (en)
Other versions
ES549285A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24710234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8703525(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of ES8703525A1 publication Critical patent/ES8703525A1/es
Publication of ES549285A0 publication Critical patent/ES549285A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

METODO PARA PREPARAR UNA VACUNA VIVA NO VIRULENTA. CONSISTENTE EN: A) MUTAR UNA CEPA DEL MICROORGANISMO PATOGENO PRODUCTORA DE RESPUESTA INMUNE, PARA PRODUCIR AL MENOS UNA MUTACION SIN REVERSION DEL PRIMER GEN, DEL GRUPO DE GENES ARO, PUR O PAB, POR SUPRESION O INVERSION Y EXPRESAR DICHO PRIMER GEN UNA PROTEINA POR BIOSINTESIS, DANDO COMO RESULTADO UN PRIMER MUTANTE AUXOTROFO NO VIRULENTO; B) SELECCIONAR DICHO MUTANTE AUXOTROFO PARA PRODUCIR SIN REVERSION DE UN SEGUNDO GEN, DEL GRUPO AVO, PUR, PAB PERO DISTINTO DEL ANTERIOR, POR SUPRESION O INVERSION EXPRESANDO UNA PROTEINA POR UNA SEGUNDA VIA DE BIOSINTESIS, DANDO COMO RESULTADO UN SEGUNDO MUTANTE; Y D) SELECCIONAR Y AISLAR DICHO SEGUNDO MUTANTE SIN REVERSION.
ES549285A 1984-11-27 1985-11-26 Un metodo para preparar una vacuna viva, no virulenta Expired ES8703525A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/675,381 US4735801A (en) 1982-09-07 1984-11-27 Novel non-reverting salmonella live vaccines

Publications (2)

Publication Number Publication Date
ES8703525A1 true ES8703525A1 (es) 1987-02-16
ES549285A0 ES549285A0 (es) 1987-02-16

Family

ID=24710234

Family Applications (1)

Application Number Title Priority Date Filing Date
ES549285A Expired ES8703525A1 (es) 1984-11-27 1985-11-26 Un metodo para preparar una vacuna viva, no virulenta

Country Status (12)

Country Link
US (1) US4735801A (es)
EP (1) EP0184086B1 (es)
JP (1) JP2610016B2 (es)
AT (1) ATE132901T1 (es)
AU (1) AU584963B2 (es)
CA (1) CA1259934A (es)
DE (1) DE3588076T2 (es)
DK (1) DK174969B1 (es)
ES (1) ES8703525A1 (es)
IE (1) IE72975B1 (es)
IL (1) IL77166A (es)
WO (1) WO1986003123A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5643771A (en) * 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
CA1338457C (en) * 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5162226A (en) * 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
GB8730037D0 (en) * 1987-12-23 1988-02-03 Wellcome Found Vaccines
US5811105A (en) * 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
EP0419513B1 (en) * 1988-05-05 1995-04-26 American Cyanamid Company Recombinant flagellin vaccines
US5762941A (en) * 1988-07-15 1998-06-09 Institut Pasteur Modified shigella having reduced pathogenicity
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
NZ232097A (en) * 1989-01-12 1992-03-26 Commw Scient Ind Res Org Smooth aromatic-dependent (aro - ) non-reverting avirulent salmonella strain, vaccine, antibodies raised against it and diagnostic kit for salmonella detection
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
IE61635B1 (en) * 1990-03-13 1994-11-16 Trinity College Dublin Improvements in vaccines
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5843426A (en) * 1990-12-18 1998-12-01 The General Hospital Corporation Salmonella vaccines
US5695983A (en) * 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
TW201794B (es) * 1991-05-03 1993-03-11 American Cyanamid Co
US5663317A (en) * 1992-03-02 1997-09-02 The Board Of Trustees Of The Leland Stanford Jr. Univ. Microorganism having attenuated invasiveness
EP0668779A4 (en) * 1992-11-06 1996-08-21 Univ Minnesota Vaccine to protect against pasteurellosis - infection by P.multocida.
DE4333742A1 (de) * 1993-10-04 1995-04-06 Klaus Prof Dr Linde Lebendimpfstoff mit erhöhter Stabilität
JPH07206705A (ja) * 1993-11-03 1995-08-08 American Cyanamid Co 生インオボ（ｉｎ ｏｖｏ）ワクチン
AU719411B2 (en) * 1993-11-03 2000-05-11 Zoetis Whc 2 Llc Live in ovo vaccine
US6793927B1 (en) * 1993-12-06 2004-09-21 The United States Of America As Represented By The Secretary Of The Department Of Agriculture Construction of Pasteurella haemolytica vaccines
US5587305A (en) * 1993-12-06 1996-12-24 The United States Of America As Represented By The Department Of Agriculture Pasteurella haemolytica transformants
US5939075A (en) * 1994-11-04 1999-08-17 The United States Of America As Represented By The Secretary Of The Army Mutants of Brucella melitensis
US6254874B1 (en) 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
US6495146B1 (en) 1995-06-07 2002-12-17 Pfizer Incorporated In ovo vaccination against coccidiosis
MX9709868A (es) * 1995-06-07 1998-03-31 Pfizer Uso de esporfozoitos o merozoitos de eimeria para preparar una vacuna contra la coccidiosis.
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US6627205B2 (en) 1997-12-01 2003-09-30 Pfizer Incorporated Ovo vaccination against coccidiosis
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
NZ529507A (en) 1998-12-02 2005-05-27 Univ Maryland Plasmid maintenance system for antigen delivery
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US6984378B1 (en) 1999-02-26 2006-01-10 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
US6482632B1 (en) 1999-03-29 2002-11-19 Council Of Scientic And Industrial Research Bacteriophage, a process for the isolation thereof, and a universal growth medium useful in the process thereof
EP1041141B1 (en) * 1999-03-30 2006-02-08 Council Of Scientific And Industrial Research A novel bacteriophage, a process for the isolation thereof and a universal growth medium useful in the process thereof
AU780887B2 (en) 1999-04-09 2005-04-21 Zoetis Services Llc Anti-bacterial vaccine compositions
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
BRPI0211870B1 (pt) 2001-08-30 2016-01-12 Embrex Inc método para esporulação de oocistos viáveis de eimeria
US20050180985A9 (en) * 2001-10-04 2005-08-18 Vladoianu Ion R. Live attenuated salmonella strains for producing monovalent or multivalent vaccines
NZ554331A (en) 2004-09-23 2009-04-30 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
JP2009544279A (ja) 2006-06-27 2009-12-17 オーラル ヘルス オーストラリア ピーティーワイ リミテッド 歯周病の予防に有用なポルフィロモナス・ジンジバリスポリペプチド
CN103357014A (zh) 2007-07-12 2013-10-23 口腔健康澳洲私人有限公司 生物膜治疗
JP2010532766A (ja) 2007-07-12 2010-10-14 オーラル ヘルス オーストラリア ピーティーワイ リミテッド バイオフィルムに対する免疫学的治療
DK2328914T3 (en) 2008-08-29 2017-07-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P. gingivalis infection
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US11413819B2 (en) 2020-09-03 2022-08-16 NEXA3D Inc. Multi-material membrane for vat polymerization printer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530275A1 (de) * 1975-07-07 1977-01-27 Max Planck Gesellschaft Salmonella-coli-hybride, verfahren zu deren herstellung und vermehrung und apathogener lebend-impfstoff gegen salmonellosen
DE2843295A1 (de) * 1978-10-04 1980-10-30 Inst Impfstoffe Dessau Verfahren zur herstellung stabiler avirulenter und hochimmunogener bakterienmutanten fuer lebendimpfstoffe
US4336336A (en) * 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
US4337314A (en) * 1979-05-23 1982-06-29 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4632830A (en) * 1981-07-31 1986-12-30 The United States Of America As Represented By The Secretary Of The Army Oral vaccine for immunization against enteric disease

Also Published As

Publication number Publication date
US4735801A (en) 1988-04-05
WO1986003123A1 (en) 1986-06-05
IE72975B1 (en) 1997-05-07
IL77166A0 (en) 1986-04-29
DK174969B1 (da) 2004-04-05
DE3588076T2 (de) 1996-05-23
EP0184086A2 (en) 1986-06-11
IL77166A (en) 1992-02-16
DE3588076D1 (de) 1996-02-22
JP2610016B2 (ja) 1997-05-14
ES549285A0 (es) 1987-02-16
DK353686A (da) 1986-07-25
DK353686D0 (da) 1986-07-25
ATE132901T1 (de) 1996-01-15
AU5196686A (en) 1986-06-18
AU584963B2 (en) 1989-06-08
CA1259934A (en) 1989-09-26
IE852963L (en) 1986-05-27
JPS62501211A (ja) 1987-05-14
EP0184086B1 (en) 1996-01-10
EP0184086A3 (en) 1987-12-16

Similar Documents

Publication Publication Date Title
ES8703525A1 (es) Un metodo para preparar una vacuna viva, no virulenta
EP0368966A4 (en) Novel non-reverting shigella live vaccines
US5393671A (en) Mutant Escherichia coli capable of enhanced L-glutamic acid production
EP0600463B1 (en) Process for producing L-tryptophan, L-tyrosine or L-Phenylalanine
HU911440D0 (en) Process for producing polypeptones
EP0672116A4 (en) DELETION MUTANTS USED AS CHOLERA VACCINES.
EP0066129A3 (en) Method for producing l-threonine by fermentation
US5017482A (en) Process for producing L-arginine
DE60132277T2 (de) L-Glutaminsäure herstellendes Bacterium und Verfahren zur Herstellung von Glutaminsäure
ZA918876B (en) Avirulent microbes and uses therefor:salmonella typhi
EP0436886B1 (de) Verfahren zur Herstellung von L-Isoleucin und dafür geeignete Mikroorganismen und rekombinante DNA
EP0349121A3 (en) Method for producing clavulanic acid
JPH0362395B2 (es)
ES8303522A1 (es) Procedimiento para la mutacion doble de virus del genero herpes
ES8703487A1 (es) Procedimiento para la preparacion de a-l-aspartil-l-fenila- lanina metil ester
EP0085958A3 (en) Method for producing l-phenylalanine by fermentation
DE69334208T2 (de) Verfahren für die Produktion von L-Threonin mittels Fermentation
HUT44288A (en) Process for production of d-(-)-lactid acid
Plachy Lysine production by auxotrophic-regulatory mutants of Corynebacterium glutamicum.
JPS6234392B2 (es)
JPS6155956B2 (es)

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20041207